In the present research, we studied the anticancer mechanism of AST, including the changes in cell ultrastructure, such as the mitochondrion, rough endoplasmic reticulum (RER), Golgi complex, and cytoskeleton, the inhibition of Janus kinase 1(JAK1)/transduction and the activators of the transcription-3 (STAT3) signaling pathway using rat hepatocellular carcinoma CBRH-7919 cells.
What does JAK stand for?
JAK stands for Janus Kinase (aka Just Another Kinase)
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of JAK
We have 11 other meanings of JAK in our Acronym Attic
- Japan Agricultural Journalists' Association
- Justice for Aquino Justice for All
- Just Another Jabber Client
- Jonathan Alder Junior High School (Ohio)
- January, April, July and October (option cycle)
- Japan-Australia Jazz Orchestra
- Jewish Alliance for Justice and Peace (Chicago, IL)
- Jessie and James Romance Novels (Pokemon fan fiction)
- J. Ashburn Jr. Youth Center (Columbus, OH)
- Jakovlev (Soviet aircraft designer)
- Japanese Association at Kearney (University of Nebraska, Kearney)
- Jayne Ann Krentz (author; aka Amanda Quick and Jayne Castle)
- Jazakom Allaho Khairan (Arabic: May Allah Reward You; Thank You)
- Journalists Association of Korea (South Korea)
- Just Another Kinase (aka Janus Kinase)
- Janus Kinase and Signal Transducer and Activator of Transcription (cytology)
- Janus Kinase/Signal Transducer and Activator of Transcription
- Janus-Activated Kinase 1
- Janus Family Kinase-2 (endocrinology)
- Janus-Activated Kinase 2
Samples in periodicals archive:
When the so-called Janus kinases are inhibited, painful immune reactions are reduced.
Two targets, janus kinase (JAK) and spleen tyrosine kinase (Syk), are promising at this time and have good data to possibly support their use.
They identified mutations in the Janus kinase 3 (JAK3) gene that seemed to have a major role in driving the cancer in a significant number of patients.
TareGen's TG101348 aims to block the effects of an enzyme known as Janus kinase 2, Sanofi said.
Vertex Pharmaceuticals Incorporated (Cambridge, MA) has patented human Janus Kinase 3 (JAK3) and JAK3-like binding pockets.